Xaira Therapeutics
Generative AI for antibodies and proteins
Ranked #2 in Best AI Drug Discovery Startups.
Xaira Therapeutics, based in South San Francisco, launched in April 2024 with more than $1 billion in committed funding. Led by former Stanford president Marc Tessier-Lavigne, it pairs generative protein design with large in-house biological datasets.
At a glance
| Price from | Custom |
| Best for | Pharma partners interested in AI-designed antibodies |
From Xaira Therapeutics's own website.
What stands out
- Over $1 billion in launch funding
- Builds its own models and lab datasets
Worth knowing
- Programs still preclinical
- No partner deals disclosed
How it ranks
Xaira Therapeutics is ranked 2nd of 10 in Best AI Drug Discovery Startups (Lister Score 95.8).
#2 in Best AI Drug Discovery Startups · Lister Score 95.8
Xaira released X-Cell, a virtual cell model, in March 2026 and showed its X-Design antibody platform in October 2026..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does Xaira Therapeutics rank on Lister?
Xaira Therapeutics is ranked 2nd of 10 in Best AI Drug Discovery Startups (Lister Score 95.8).
Appears in
Add this badge to your site
If you work at Xaira Therapeutics, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.